insulin aspart + insulin glulisine

Insulin aspart + insulin glulisine is a combination of two rapid/fast-acting synthetic insulins used for glycemic control in people with diabetes mellitus, including both type 1 and type 2 diabetes. Both agents are recombinant analogs of human insulin designed to be absorbed quickly after subcutaneous injection, typically administered at mealtimes to manage postprandial blood glucose spikes. They act by binding to the human insulin receptor, stimulating glucose uptake into muscle and fat tissue while inhibiting hepatic glucose production. Insulin aspart is marketed under brand names such as NovoLog and Fiasp, while insulin glulisine is marketed primarily under the brand name Apidra. These drugs are developed and manufactured by different companies (Novo Nordisk for aspart; Sanofi for glulisine) but may be co-administered or compared in clinical practice due to their similar pharmacokinetic profiles[1][2][3][4][5][6][8].

Brand names

Apidra OptiClik CartridgeApidra SoloStar Pen

Other names

NovoLOG FlexPenNovoLOG PenFillNovoLOG FlexTouch